Information Technology
Capgemini reveals gen AI-driven breakthrough to accelerate the bioeconomy
Press contact:
Mollie Mellows
Tel.: + 44 (0) 7342 709384
E-mail: mollie.mellows@capgemini.com
Capgemini reveals gen AI-driven breakthrough to accelerate the bioeconomy
New methodology reduces the data requirements for protein engineering by 99% so organizations can unlock innovation even in resource-constrained environments
Paris, February 10, 2025 – Capgemini today announced a new generative AI-driven methodology for protein engineering that uses a specialized protein large language model (pLLM) to predict the most effective protein variants. With a patent pending, this novel approach will help accelerate the advancement of the global bioeconomy and drive critical scientific breakthroughs across industries including healthcare, agriculture, and environmental science. By reducing the datapoints required to design protein sequences by over 99%, the new methodology harnesses the power of generative AI (gen AI) to drastically reduce the time and resources needed for research and development (R&D). Using this approach, Capgemini can help clients reduce the development cost of biosolutions and unlock business cases that were not previously viable.
Breakthrough solves the data bottleneck challenge
Advancements in engineering biology are expected to disrupt all industries, with half of business leaders predicting this transformation will happen within the next five years. However, data can be a critical bottleneck in research timelines. This new methodology makes scientific breakthroughs possible with significantly smaller data sets, enabling organizations to innovate even in resource-constrained environments. Using this novel approach, Capgemini is exceptionally positioned to help clients find and develop innovative solutions to global challenges such as disease, food security, and climate concerns.
The methodology was created in the bespoke gen AI-driven biotechnology lab of Cambridge Consultants, the deep tech powerhouse of the Capgemini Group. The methodology was applied to several critical use cases to demonstrate how it could drive a step-change in innovation. Examples that can be readily translated to other applications include:
“Capgemini's proprietary generative AI-driven approach means we are uniquely placed to enable clients to significantly accelerate their bio-journey in previously untapped areas and, crucially, contribute to helping solve many of humanity's most pressing challenges,” said Roshan Gya, CEO of Capgemini Invent and member of the Group Executive Board . “Our new methodology is faster, more cost-effective, and opens the door to new opportunities for clients to develop innovative bio-based solutions. The Capgemini Group delivers end-to-end engineering biology and scale-up capabilities so that our clients can derive significant business value and develop proprietary IP, moving away from traditional carbon-based approaches and fueling growth in the bioeconomy.”
Prof. Stephen Wallace, Professor of Chemical Biotechnology at the University of Edinburgh, stated: “Capgemini's generative AI-driven approach represents a significant leap in protein engineering. By drastically reducing data requirements, Capgemini has fundamentally transformed the innovation timeline in bioengineering. This breakthrough reflects a clear vision for the future of engineering biology, leveraging the design and engineering of new biocatalysts to enable more sustainable and scalable industrial processes. With its expertise and adaptability, Capgemini is well-positioned to drive technological advances in this exciting and rapidly evolving interdisciplinary field.”
Building on 10 years of pioneering engineering biology and AI development, the bespoke AI-driven biotechnology lab at Cambridge Consultants has been created at its UK headquarters, home to an unrivalled combination of multidisciplinary experts in biology, chemistry, gen AI, digital twins, electronics, software, sustainability and more.
About Capgemini
Capgemini is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2023 global revenues of €22.5 billion.
Get The Future You Want | www.capgemini.com
A priority patent application has been submitted in GB – patent pending
The bioeconomy refers to economic activity that relies on biological resources and processes (animals, plants, microorganisms, and biomass)
Engineering biology is also known as synthetic biology
“Unlocking the power of engineering biology: The time is now”, Capgemini Research Institute, July 2024
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti